SOURCE: Beluzzi et al., 1996. Effect of an Enteric-Coated Fish-Oil Preparation on Relapses in Crohn’s Disease
Maintaining remission in Crohn’s disease remains one of the most persistent challenges in our clinical practice. While our armamentarium of biologics and advanced small molecules has expanded significantly in recent years, many of our patients remain understandably wary of long-term immunosuppression. It is within this context of “therapeutic fatigue” that the study by Belluzzi and colleagues—published in The New England Journal of Medicine—demands our attention, not merely as a clinical trial, but as a potential shift in how we approach the high-risk patient in clinical remission.
The “Why Now?”: Contextualising Remission
For years, the standard of care has leant heavily on aminosalicylates like mesalamine, despite their often underwhelming efficacy in the maintenance of Crohn’s. Belluzzi’s team targeted a particularly precarious subgroup: patients in clinical remission who nonetheless exhibited elevated inflammatory markers—a population we know carries a 75% higher risk of imminent relapse.
The study investigated a novel, enteric-coated fish-oil preparation, delivering 2.7 g of $n-3$ fatty acids daily. The results were, frankly, striking. At the end of one year, 59% of the fish-oil group remained in remission, compared to a sobering 26% in the placebo cohort.
“The nearly 41-percentage-point difference in relapse rates isn’t just statistically significant; it’s clinically transformative for a patient population that often feels they are just waiting for the next flare.”
The Surprise: Beyond the “Fishy” Reputation
Perhaps the most unexpected element of this data was the high level of compliance and the relative lack of standard “fish oil” side effects. Historically, our patients have abandoned fish oil due to the “triple threat” of halitosis, belching, and heartburn. By using a specialised coating designed to bypass the stomach and disintegrate in the small intestine, Belluzzi et al. managed to significantly reduce these barriers.
Interestingly, the laboratory data mirrored the clinical outcomes. We saw a significant decrease in the erythrocyte sedimentation rate (ESR) and alpha1 acid glycoprotein in the fish-oil group. Even more compelling was the gas chromatography analysis of red-cell membranes, which showed omega-3 fatty acids almost completely displacing arachidonic acid. This suggests that the fish oil wasn’t just a “supplement” but was fundamentally altering the pro-inflammatory phospholipid profile of these patients.
A Signal in the Noise: The Diarrhoea Dilemma
It is worth noting, however, that the study was not without its “safety signals”. Four patients in the fish-oil group (10%) withdrew due to diarrhoea. In my experience, this is the nuance that requires careful patient selection. The authors suggest this may be due to the enteric coating delivering the oil too far into the distal gut, especially in patients with rapid transit.
“While the efficacy data is robust, the safety signal regarding diarrhoea warrants careful patient selection, particularly in those with existing malabsorptive symptoms or significant prior resections.”
The Practice Change: How Should We Prescribe?
So, how does this change our Monday morning clinic? Firstly, it validates omega-3 fatty acids not as a “wellness” fad, but as a legitimate anti-inflammatory strategy that may work by inhibiting leukotriene B4 and thromboxane A2 synthesis.
For the patient who is currently in remission but displays “smouldering” inflammation (raised ESR or globulins) and is hesitant to start thiopurines or biologics, this enteric-coated preparation offers a potent middle ground. It is not a replacement for surgery or induction therapy, but as a maintenance tool, it appears to punch well above its weight class.
“We are finally seeing evidence that a refined nutritional intervention can compete with traditional pharmacotherapy in preventing clinical relapses.”
Final Thoughts
This study serves as a poignant reminder that the “natural” versus “pharmaceutical” divide is often a false dichotomy. By applying rigorous pharmaceutical delivery technology to a biological agent, the investigators have provided us with a high-yield, low-toxicity option for a high-risk group. While further head-to-head trials against mesalamine are needed, the evidence here is far too strong to ignore.